Syndax Pharmaceuticals develops and sells cancer medicines, including Revuforj for certain acute leukemias. SNDX reports earnings on Mon, Nov 2, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 13 | HC Wainwright & Co. | Reiterated | Buy | |
| Aug 21 | UBS | Maintained | Buy | |
| Aug 11 | JP Morgan | Maintained | Buy | |
| Aug 5 | HC Wainwright & Co. | Target lowered | Buy | |
| May 22 | HC Wainwright & Co. | Reiterated | Buy |
Whale Options Flow
90DNo whale options trades in SNDX in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SNDX is in one of them and how their past SNDX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SNDX in an article yet. Here's the latest on the wider market.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals is a biopharmaceutical company based in New York that develops and sells cancer treatments. Its two approved medicines are Revuforj, a pill for certain acute leukemias, and Niktimvo, used to treat chronic graft versus host disease. Syndax leads sales of Revuforj in the United States and works with partner Incyte on Niktimvo. Its customers are cancer patients and the doctors who treat them.
- Headquarters
- New York, NY